In conclusion, these data suggest that the oral XPO1 inhibitor selinexor, with its novel mechanism of action, can be used to treat patients with previously treated MM with either high‐risk or standard‐risk cytogenetics. This evidence concerns the gene XPO1 and Miyoshi myopathy.